EMA says disclosure policy 'will not impinge on IP rights'
This article was originally published in SRA
Executive Summary
The European Medicines Agency's new policy on clinical trial data disclosure will ensure transparency in the interests of public health without impinging on a company's intellectual property rights1. So says the agency in publishing the final advice from its five cross-sector groups that have been looking at the scientific, technical, legal and ethical issues surrounding this vexed and controversial topic.